Aquestive Therapeutics
AQST
4.62
+0.01
+0.22%
Aquestive Therapeutics
US · AQST
#3650 by market cap
Listed 2018
4.62
+0.01
+0.22%
Live - 5344 symbols - heartbeat 223s ago
· 2026-10-08 07:23
Pre-market
4.50
-2.60%
After-hours
4.62
0.00%
- Market cap
- 579.86M
- P/E (TTM)i
- -7.00
- P/Bi
- -10.24
- EPSi
- -0.78
- Div yieldi
- 0.00%
- 52W posi
- 37%
Reader sentiment
Are you bullish or bearish on AQST?
Anonymous reader poll. Unscientific, not investment advice.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
- Founded
- 2004
- CEO
- Mr. Daniel Barber
- Employees
- 147
- Headquarters
- Warren, New Jersey, United States of America
- Fiscal year end
- 12-31
- Website
- aquestive.com
Company profile
- Exchange
- US
- Symbol
- AQST
- Market-cap rank
- #3650
- Listing date
- 2018-07-25
- Market cap
- 579.86M
- Float cap
- 529.49M
- Shares out
- 125.51M
- Float shares
- 114.61M
Sectors & themes
Drug Manufacturers - Specialty & Generic
Quote time 2026-10-08 07:23:59 · For reference only, not investment advice and not tailored to your situation.